Improvements and future perspective in diagnostic tools for neuroendocrine neoplasms.
Diagnosis
genomics
liquid biopsy
neuroendocrine neoplasms
nuclear medicine
proteomics
radiomics
Journal
Expert review of endocrinology & metabolism
ISSN: 1744-8417
Titre abrégé: Expert Rev Endocrinol Metab
Pays: England
ID NLM: 101278293
Informations de publication
Date de publication:
05 Jun 2024
05 Jun 2024
Historique:
medline:
5
6
2024
pubmed:
5
6
2024
entrez:
5
6
2024
Statut:
aheadofprint
Résumé
Neuroendocrine neoplasms (NENs) represent a complex group of tumors arising from neuroendocrine cells, characterized by heterogeneous behavior and challenging diagnostics. Despite advancements in medical technology, NENs present a major challenge in early detection, often leading to delayed diagnosis and variable outcomes. This review aims to provide an in-depth analysis of current diagnostic methods as well as the evolving and future directions of diagnostic strategies for NENs. The review extensively covers the evolution of diagnostic tools for NENs, from traditional imaging and biochemical tests to advanced genomic profiling and next-generation sequencing. The emerging role of technologies such as artificial intelligence, machine learning, and liquid biopsies could improve diagnostic precision, as could the integration of imaging modalities such as positron emission tomography (PET)/magnetic resonance imaging (MRI) hybrids and innovative radiotracers. Despite progress, there is still a significant gap in the early diagnosis of NENs. Bridging this diagnostic gap and integrating advanced technologies and precision medicine are crucial to improving patient outcomes. However, challenges such as low clinical awareness, limited possibility of noninvasive diagnostic tools and funding limitations for rare diseases like NENs are acknowledged.
Identifiants
pubmed: 38836602
doi: 10.1080/17446651.2024.2363537
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM